Bagheri, Abouzar <br/><br/>
Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells.  [electronic resource] 

 -  Molecular vision  2015 
 - 378-90 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1090-0535 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Actins--genetics<br/>Angiogenesis Inhibitors--pharmacology<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antibodies, Neutralizing--pharmacology<br/>Apoptosis--drug effects<br/>Bevacizumab<br/>Cathepsin D--genetics<br/>Cell Proliferation--drug effects<br/>Connective Tissue Growth Factor--antagonists & inhibitors<br/>Drug Synergism<br/>Epithelial Cells--cytology<br/>Gene Expression Regulation<br/>Humans<br/>Matrix Metalloproteinase 2--genetics<br/>Matrix Metalloproteinase 9--genetics<br/>Primary Cell Culture<br/>Retinal Pigment Epithelium--cytology<br/>Signal Transduction<br/>Tissue Inhibitor of Metalloproteinase-1--genetics<br/>Tissue Inhibitor of Metalloproteinase-2--genetics<br/>Transcription, Genetic<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Vascular Endothelial Growth Factor Receptor-1--genetics